(Q38178771)

30 August 2017

Early lung disease in cystic fibrosis (English)

1 reference

30 August 2017

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Hartmut Grasemann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

12 March 2013

1 reference

The Lancet. Respiratory medicine

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

148-157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Cystic fibrosis mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Modifier gene studies to identify new therapeutic targets in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Genetic modifiers of liver disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lower airway inflammation in infants and young children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Infection, inflammation, and lung function decline in infants with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Early Cystic Fibrosis Lung Disease Detected by Bronchoalveolar Lavage and Lung Clearance Index

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Safety of bronchoalveolar lavage in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Morphologic and functional scoring of cystic fibrosis lung disease using MRI

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Proton MRI appearance of cystic fibrosis: Comparison to CT

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lung function testing in infants with cystic fibrosis: lessons from the past and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lung Function in Infants with Cystic Fibrosis Diagnosed by Newborn Screening

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Spirometry in early childhood in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Respiratory tract mucin genes and mucin glycoproteins in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Restoring airway surface liquid in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Sputum induction in routine clinical care of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Use of modulators of airways inflammation in patients with CF.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970026-2

7 January 2021

10.1016/S2213-2600(13)70026-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429095%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference